{"id":59395,"date":"2026-03-13T21:27:24","date_gmt":"2026-03-13T13:27:24","guid":{"rendered":"https:\/\/flcube.com\/?p=59395"},"modified":"2026-03-13T21:27:25","modified_gmt":"2026-03-13T13:27:25","slug":"luye-pharma-signs-strategic-partnership-with-sinopharm-mimeixin-distribution-deal-targets-chinas-severe-pain-market","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=59395","title":{"rendered":"Luye Pharma Signs Strategic Partnership with Sinopharm \u2013 Mimeixin Distribution Deal Targets China’s Severe Pain Market"},"content":{"rendered":"\n

Luye Pharma Group Limited<\/strong> (HKG: 2186<\/a>) announced a strategic cooperation agreement<\/strong> with Sinopharm Group Co., Ltd.<\/strong> to drive channel distribution, market access, and resource synergy<\/strong> across multiple Luye Pharma products. The partnership designates Mimeixin (Oxycodone and Naloxone Prolonged\u2011release Tablets)<\/strong> as the flagship collaboration asset, leveraging Sinopharm’s national distribution network to expand reach for China’s first oral naloxone\u2011containing analgesic<\/strong> following its 2025 NRDL inclusion<\/strong>.<\/p>\n\n\n\n

Partnership Framework<\/h2>\n\n\n\n
Element<\/th>Detail<\/th><\/tr><\/thead>
Parties<\/strong><\/td>Luye Pharma Group (HKG: 2186) + Sinopharm Group Co., Ltd.<\/td><\/tr>
Agreement Type<\/strong><\/td>Strategic cooperation (channel distribution focus)<\/td><\/tr>
Flagship Product<\/strong><\/td>Mimeixin (Oxycodone\/Naloxone Prolonged\u2011release Tablets)<\/td><\/tr>
Scope<\/strong><\/td>Multi\u2011product collaboration across distribution, market access, resource integration<\/td><\/tr>
Signing Date<\/strong><\/td>13\u202fMar\u202f2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Mimeixin Product Profile<\/h2>\n\n\n\n
Attribute<\/th>Specification<\/th><\/tr><\/thead>
Composition<\/strong><\/td>Oxycodone (opioid agonist) + Naloxone (opioid antagonist) prolonged\u2011release<\/td><\/tr>
Indication<\/strong><\/td>Severe pain in adults requiring opioid analgesics<\/td><\/tr>
Mechanism<\/strong><\/td>Naloxone blocks intestinal opioid receptors \u2192 relieves opioid\u2011induced constipation (OIC)<\/strong> without compromising systemic analgesia<\/td><\/tr>
Market Position<\/strong><\/td>China’s first<\/strong> oral naloxone\u2011containing analgesic; only innovative combination<\/strong> providing potent analgesia + mechanistic OIC resolution<\/td><\/tr>
Reimbursement Status<\/strong><\/td>NRDL included (2025)<\/strong> \u2013 national reimbursement coverage secured<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Strategic Rationale & Market Impact<\/h2>\n\n\n\n
Factor<\/th>Implication<\/th><\/tr><\/thead>
Distribution Scale<\/strong><\/td>Sinopharm’s 30,000+ hospital network<\/strong> and tier\u20111\/2\/3 city coverage<\/strong> accelerates Mimeixin penetration vs. Luye standalone commercialization<\/td><\/tr>
NRDL Leverage<\/strong><\/td>2025 reimbursement listing enables rapid volume ramp with Sinopharm’s government hospital relationships<\/td><\/tr>
Competitive Moat<\/strong><\/td>First\u2011mover advantage in OIC\u2011addressing opioid segment vs. pure oxycodone generics (OxyContin) and tapentadol<\/td><\/tr>
Pain Market Size<\/strong><\/td>China severe pain market estimated RMB 12\u201115 billion<\/strong>; opioid analgesics ~40% share with growing demand for tolerability\u2011enhanced formulations<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n